Abstract
Thirty-one postmenopausal patients with advanced breast cancer either unresponsive to tamoxifen or progressing after responding to tamoxifen were treated with aminoglutethimide (1 000 - 1 250 mg/d) plus hydrocortisone replacement. The response rate was 33% in patients who had never responded to tamoxifen and 47% in patients who had previously responded to tamoxifen. The overall response rate was 42%. These results show that aminoglutethimide is an effective second-line hormonal treatment for patients with advanced breast cancer.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aminoglutethimide / administration & dosage
-
Aminoglutethimide / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Breast Neoplasms / drug therapy*
-
Cyclophosphamide / administration & dosage
-
Female
-
Fluorouracil / administration & dosage
-
Fluoxymesterone / administration & dosage
-
Humans
-
Menopause
-
Methotrexate / administration & dosage
-
Tamoxifen / therapeutic use*
-
Time Factors
Substances
-
Tamoxifen
-
Aminoglutethimide
-
Cyclophosphamide
-
Fluoxymesterone
-
Fluorouracil
-
Methotrexate